CONSOLIDATED STATEMENTS OF CASH FLOWS $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)
Cash flows from operating activities:
Net loss	$ (29,059)	$ (29,511)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	4,572	2,193
Stock-based compensation expense	14,067	7,330
Acquired in-process research and development expenses	27,212
Deferred taxes	(1,540)
Loss on extinguishment of debt		575
Loss on sale of marketable securities		107
Non-cash interest expense and end of term accretion expense	1,358	309
Non-cash lease expense	728	532
Net amortization of premiums on marketable securities		381
Unrealized foreign currency transaction losses	118	1,733
Changes in operating assets and liabilities, net of acquired assets and liabilities:
Accounts receivable	(30,997)	(16,287)
Inventory	(21,029)	(6,094)
Prepaid expenses and other current assets	(2,170)	(98)
Other non-current assets	(54)
Accounts payable	6,541	(3,534)
Accrued expenses and other current liabilities	9,257	(8)
Deferred revenue	765
Operating lease liabilities	(1,101)	590
Net cash used in operating activities	(21,332)	(41,782)
Cash flows from investing activities:
Purchases of property, plant and equipment	(110,029)	(9,143)
Purchase of business, net of cash acquired	(14,894)
Purchase of in-process research and development assets	(27,212)
Purchases of marketable securities		(10,496)
Proceeds from sales and maturities of marketable securities		76,916
Net cash provided by (used in) investing activities	(152,135)	57,277
Cash flows from financing activities:
Proceeds from issuance of convertible senior notes, net of issuance costs paid of $14,620	445,380
Purchases of capped calls related to convertible senior notes	(52,072)
Proceeds from issuance of long-term debt, net of issuance costs and issuance costs paid		58,509
Repayments of long-term debt		(36,050)
Proceeds from issuance of common stock in public offering, net of underwriting discounts and commissions		140,014
Proceeds from issuance of common stock upon exercise of stock options	5,231	1,880
Proceeds from issuance of common stock in connection with employee stock purchase plan	955	509
Net cash provided by financing activities	399,494	164,862
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(99)	(1,475)
Net increase in cash, cash equivalents and restricted cash	225,928	178,882
Cash, cash equivalents and restricted cash, beginning of period	201,682	26,080
Cash, cash equivalents and restricted cash, end of period	427,610	204,962
Supplemental disclosure of non-cash investing and financing activities:
Transfers of inventory to property, plant and equipment	2,224	2,055
Purchases of property, plant and equipment included in accounts payable and accrued expenses	1,724	926
Operating lease liabilities arising from obtaining right-of-use assets	2,171
Offering costs included in accounts payable and accrued expenses		160
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	427,110	204,462
Restricted cash	500	500
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$ 427,610	$ 204,962